Onconetix, Inc. filings document the regulatory record of a Nasdaq-listed biotechnology company focused on men's health and oncology diagnostics. Registration statements, amendments, proxy materials, and current reports describe securities offerings, preferred stock and warrant terms, common-stock structure, shareholder voting matters, and reverse-stock-split authorizations.
The company's SEC reports also disclose governance changes, board and executive appointments, material agreements, operating and financial results, clinical or regulatory matters, and risk factors related to its commercial-stage biotechnology business and Proclarix prostate cancer diagnostic.
Onconetix, Inc. filed an 8-K to highlight Q1 2026 progress at its fully owned Swiss subsidiary Proteomedix AG, developer of the Proclarix® blood test for clinically significant prostate cancer. The company reported two new peer-reviewed publications from a Danish clinical study, including a paper in BMC Cancer showing Proclarix® evaluated in 371 men and outperforming %fPSA and the ERSPC risk calculator in reducing overdiagnosis and unnecessary biopsies. A second paper in Cancers, in 132 men under active surveillance, showed the prognostic value of the Proclarix® risk score for predicting transition to active treatment. Onconetix also announced the PRIME multi-center clinical validation study with Labcorp in the U.S., targeting up to 500 men across various ethnicities, and early commercial traction in Europe, including close to 100 Proclarix® tests performed in a UK real-world screening initiative and progress with a new collaboration partner in Turkey.
Onconetix, Inc. reported a first‑quarter 2026 net loss of $4.2 million, narrower than $8.5 million a year earlier, driven largely by non‑cash items. Revenue fell to $21,457 from $101,630, all from Proclarix diagnostics, resulting in a small gross loss.
The company recorded a further goodwill impairment of about $8.1 million, reducing goodwill to $10.2 million. A large favorable change in the fair value of Series D and Series E derivative liabilities added other income of about $6.0 million, partly offsetting operating losses.
Cash was $3.7 million at March 31, 2026, with about $2.1 million used in operating activities during the quarter. Management discloses substantial doubt about the company’s ability to continue as a going concern, noting ongoing losses, limited cash and no committed financing.
Capital structure is highly complex, with multiple preferred series, warrants and an equity line of credit. Subsequent to quarter‑end, conversions of Series D and Series E preferred stock and an ELOC draw increased common shares outstanding to 11,464,572 by May 12, 2026, significantly diluting existing holders. Onconetix also signed a Share Exchange Agreement with Realbotix Corp. that could transfer 75–90% of fully diluted equity to Realbotix’s owner, contingent on minimum net cash, an additional equity line and full conversion of its preferred stock.
Onconetix is registering up to 25,000,000 shares of Common Stock for resale on behalf of Keystone Capital Partners under an equity line of credit (ELOC). The registration covers shares that have been or may be issued to Keystone under a Common Stock ELOC Purchase Agreement.
The Company will not receive proceeds from resale under this prospectus, but may receive up to $25.0 million in aggregate gross proceeds from Keystone under the ELOC Purchase Agreement. Through April 24, 2026, the Company sold approximately 701,933 split-adjusted shares under the ELOC for aggregate proceeds of approximately $8.1 million. Shares outstanding were 11,464,572 as of April 24, 2026; if all ELOC shares were issued, pro forma outstanding would be 36,464,572 shares (assuming the illustrative pricing described in the ELOC).
Onconetix, Inc. filed Amendment No. 1 to its Form S-1 registration statement, mainly to add a new legal opinion as Exhibit 5.1 from Ellenoff Grossman & Schole LLP regarding the legality of the securities being registered. The amendment is described as an exhibit-only filing, with the remainder of the registration statement unchanged and omitted from this document.
The filing states that the proposed sale of securities may occur from time to time after the registration statement becomes effective. It also lists extensive corporate, financing, equity plan, and commercial agreements as exhibits and is signed on behalf of Onconetix by Chief Executive Officer David A. White and other directors and officers.
Onconetix, Inc. filed a Post-Effective Amendment No. 1 on Form S-1 to register 38,769,702 shares of Common Stock for resale by selling stockholders, consisting of shares issuable upon adjustment and exercise of previously issued Series D and Series E warrants. The registration covers resale only; the company will receive cash proceeds only if the warrants are exercised for cash. The prospectus discloses a one-for-five reverse stock split effective March 25, 2026, recent Series D/E PIPE financings, a pending Share Exchange Agreement to acquire Realbotix subject to customary closing conditions and a disclosed going concern risk with cash of $5.2M as of December 31, 2025 and approximately $4.0M as of May 4, 2026.
Onconetix, Inc. held a special meeting of stockholders on April 30, 2026, where stockholders approved a reverse stock split proposal and an adjournment proposal. Voting was based on 3,464,686 shares of common stock outstanding as of March 13, 2026, the record date.
The reverse stock split proposal received 1,301,918 votes for, 253,378 against and 1,393 abstentions. The adjournment proposal received 1,332,088 votes for, 223,071 against and 1,530 abstentions, meaning both items on the agenda were approved.
Onconetix, Inc. files an S-1 registering 25,000,000 shares of common stock for resale by Keystone Capital Partners under an equity line of credit. The company is not selling these shares itself but may receive up to $25.0 million as it issues stock to Keystone.
Through April 24, 2026, Onconetix sold about 701,933 split-adjusted shares under the equity line for roughly $8.1 million. As of December 31, 2025, it reported cash of about $5.2 million, a working capital deficit of roughly $3.1 million, and an accumulated deficit near $131.2 million, leading auditors to raise substantial doubt about its ability to continue as a going concern.
The filing also highlights a pending Share Exchange Agreement with Realbotix that could give Realbotix’s owner 75%–90% of fully diluted shares depending on Onconetix’s net cash at closing, implying major future dilution alongside existing PIPE financings and a recent one-for-five reverse stock split.
Onconetix, Inc. announced multiple board changes. Effective April 20, 2026, directors Andrew Oakley and Thomas Meier resigned from the board and their committee roles. Their departures were stated as not resulting from any disagreement with management or the board on company matters.
On April 23, 2026, existing director Sammy Dorf was appointed Chairman of the Board and will receive an additional $20,000 per year, paid quarterly, for this role. The board also elected Josh Epstein as a Class II director and member of the Audit Committee and Compensation Committee, and chair of the Nominating and Corporate Governance Committee, with a term running until the 2026 annual meeting of stockholders.